Jade Biosciences, Inc. Operating Lease, Expense
Jade Biosciences, Inc. (JBIO) reported Operating Lease, Expense of $51.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-10
- Jade Biosciences, Inc. operating lease, expense for the quarter ending 2026-06-30 was $25.00K, a 62.12% decline year-over-year.
- Jade Biosciences, Inc. operating lease, expense for the quarter ending 2026-03-31 was $26.00K, a 225.00% increase year-over-year.
- Jade Biosciences, Inc. operating lease, expense for the quarter ending 2025-12-31 was $26.00K.
- Jade Biosciences, Inc. operating lease, expense for the quarter ending 2025-09-30 was -$17.00K.
- Jade Biosciences, Inc. operating lease, expense for fiscal 2025 was $83.00K.
- Jade Biosciences, Inc. operating lease, expense for fiscal 2023 was $400.00K, a 0.00% change from fiscal 2022.
- Jade Biosciences, Inc. operating lease, expense for fiscal 2022 was $400.00K, a 300.00% increase from fiscal 2021.
- Jade Biosciences, Inc. operating lease, expense for fiscal 2021 was $100.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $51.00K 10-Q · filed 2026-08-10 | $77.00K derived: sum of 3 quarters · filed 2026-08-10 | $60.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-07 | $52.00K derived: sum of 2 quarters · filed 2026-05-07 | $35.00K derived: sum of 3 quarters · filed 2026-05-07 | $101.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $9.00K derived: sum of 2 quarters · filed 2026-03-06 | $75.00K derived: sum of 3 quarters · filed 2026-08-10 | $83.00K 10-K · filed 2026-03-06 | |
| 2025-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $49.00K derived: sum of 2 quarters · filed 2026-08-10 | $57.00K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $74.00K 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $8.00K 10-Q · filed 2026-05-07 | ||||
| 2023-12-31 | $400.00K 10-K · filed 2024-03-25 | ||||
| 2022-12-31 | $400.00K 10-K · filed 2024-03-25 | ||||
| 2021-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $100.00K derived: sum of 2 quarters · filed 2023-03-29 | $100.00K 10-K · filed 2023-03-29 | $68.00K 10-K · filed 2022-03-30 | |
| 2021-09-30 | $16.00K 10-Q · filed 2021-11-15 | $16.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |